

oncoReveal™ Myeloid Panel

The **oncoReveal™ Myeloid Panel** is a robust NGS assay that interrogates 58 genes of interest* most relevant to myeloid cancer. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.

oncoReveal™ Myeloid Panel (58 genes)

| | | | | | | | | | |
|---------|--------|--------|-------|-------|-------|--------|--------|-------|-------|
| ABL1 | BRAF | CEBPA | ETV6 | HRAS | KDM6A | NPM1 | PTEN | SMC1A | TP53 |
| ANKRD26 | CALR | CSF3R | EZH2 | IDH1 | KIT | NRAS | PTPN11 | SMC3 | U2AF1 |
| ASXL1 | CBL | CUX1 | FLT3 | IDH2 | KMT2A | PDGFRA | RAD21 | SRSF2 | WT1 |
| ATRX | CBLB | DDX41 | GATA1 | IKZF1 | KRAS | PFH6 | RUNX1 | STAG1 | ZRSR2 |
| BCOR | CBLC | DNMT3A | GATA2 | JAK2 | MPL | PIGA | SETBP1 | STAG2 | |
| BCORL1 | CDKN2A | ETNK1 | GNAS | JAK3 | NF1 | PPM1D | SF3B1 | TET2 | |

Genes highlighted in orange indicate full CDS coverage

Simple NGS library prep workflow

Maintain control of samples and results with single-tube, tiled amplification that can be performed in-house by any NGS lab


Sensitive and robust chemistry

Achieve variant detection as low as 1% VAF[†] without UIDs[‡] even with limited DNA input or poor sample quality

Reduced fully-loaded lab costs

Improve lab efficiency and reduce “no calls”, repeat testing, and difficult interpretation decisions

Simple, one-day workflow



* Content is based on data from ongoing clinical trials along with sources that include the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), the National Comprehensive Cancer Network (NCCN), and the Catalog of Somatic Mutations in Cancer (COSMIC) database.

‡ UID, unique ID; also known as unique molecular ID (UMI); † VAF, variant allele frequency

Panel specifications*

| | |
|---|---|
| Enrichment chemistry | Multiplex PCR using tiled amplicons |
| Number of pools | 1 pool |
| Number of genes/amplicons | 58/766 |
| Number of targets | Full CDS coverage of 18 genes plus hotspots on 40 additional genes; ~121.6kb total size |
| Variant types | SNVs, indels, ITD (internal tandem duplicates) |
| Average amplicon size | 215bp |
| Recommended DNA input range | 10ng to 80ng (20ng recommended) |
| Sample types | Whole blood, PBMCs |
| Mapping rate | 99.6% ± 0.2% |
| % on-target aligned reads | 92.0% ± 5.3% |
| Coverage uniformity (% targets with >0.2X mean coverage) | 96.8% ± 1.0% |
| Total assay time (from DNA to sequencer) | <8 hours |
| Sequencing platforms | Illumina® sequencers |

* Mapping rate, percentage of on-target aligned reads, and coverage uniformity metrics are based on internal testing performed using reference standard materials

Ordering information

Select the panel AND one of the index kit options listed below.

| Panel | Part number |
|--|----------------|
| oncoReveal™ Myeloid Panel (24 reactions) | HDA-MY-1001-24 |

| Pillar Index Kit options | Reactions | Part number |
|-----------------------------------|--------------------------------|-----------------|
| Pillar Custom Index Primers Kit A | 32 Combinations, 96 reactions | IDX-PI-1001-96 |
| Pillar Custom Index Primers Kit D | 96 Combinations, 192 reactions | IDX-PI-1004-192 |

For more information go to:
illumina.com

illumina®

For research use only. Not for use in diagnostic procedures.
Pillar®, SLIMamp®, and oncoReveal™ are trademarks of Pillar Biosciences, Inc.
Illumina® is a trademark of Illumina, Inc.
CAP No. M-GL-02028

5200 Illumina Way
San Diego, CA 92122 USA
1.858.202.4500
info@illumina.com